Page 3 - Single Pill News Today

14.02.2023 - EQS-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023 14.02.2023 / 07:30 CET/CEST The issuer is solely responsible for the ... Seite 1

EQS-News: APONTIS PHARMA AG / Key word(s): Product Launch APONTIS PHARMA extends portfolio for the treatment of hypertension and hype...

EQS-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill 31.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA extends portfolio for the tr...

EQS-News: APONTIS PHARMA AG / Key word: 9 Month figures/Quarterly / Interim Statement APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill... | November 10, 2022

EQS-News: APONTIS PHARMA AG / Key word(s): Alliance/Product Launch APONTIS PHARMA announces cooperation to launch new Single Pill in ...

The iPhone 14 Pro and iPhone 14 Pro Max will feature physically larger batteries, according to Bloomberg's Mark Gurman, likely to compensate for...

DGAP-News: APONTIS PHARMA AG / Key word(s): Scientific publication APONTIS PHARMA: SECURE study and START study add-on analysis confi...

Investegate announcements from APONTIS PHARMA AG, APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed

DGAP-News: APONTIS PHARMA AG / Key word(s): Market launch APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis 0...

06.07.2022 - DGAP-News: APONTIS PHARMA AG / Key word(s): Market launch APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis 06.07.2022 / 07:30 The issuer is solely responsible for the content of this announcement. APONTIS PHARMA rolls out new ... Seite 1